The company has signed an agreement with distributor RubyDerm, who will be responsible for the distribution of specific Helix BioMedix branded skin care products to spas, beauty stores, hospitals, clinics, physicians and consumers.
The company has chosen to target the markets of South Korea, China and Japan in its distribution agreement – with China and South Korea both representing well above average industry growth for personal care, while Japan is already an established market for the category.
Targeting three major Asian markets
“RubyDerm Bio gives the company access to three major Asian aesthetic and dermatology markets,” said Stephen Beatty, CEO and president of Helix BioMedix
“Helix BioMedix has a proven peptide technology base for effective skin care backed by impressive science,” said Jerry Jung, CEO of RubyDerm Bio.
The distribution agreement will see Helix BioMedix Cerakine brand, which is a range of creams, skin lighterners, moisturizers, serums and masks, distributed in Asia for the first time.
SmartPeptides technology clinical results
At the end of last year Helix BioMedix revealed the results of three clinical trials designed to demonstrate the efficacy and safety of its leading SmartPeptides technology.
The studies were carried out on three different products within the Striking Skin Care range – a serum, an eye cream and a moisturizer – which all contained the SmartPeptides technology as well as its newly developed Heptapeptide-7.
Ultimately the company says the clinical trials showed that all three products had the effect of improving skin texture and appearance, as well as reducing the appearance of fine lines and wrinkles.
The company launched its first finished products line in November 2008, when it unveiled the Striking Skin Care range.